Alzinova: Positive Pre-IND meeting with FDA - Redeye
Redeye leaves a note following Alzinova's update regarding its Pre-IND meeting with the FDA. We are encouraged to learn that the company has received positive feedback on the planned clinical development program for vaccine candidate ALZ-101.
ANNONS
Redeye leaves a note following Alzinova's update regarding its Pre-IND meeting with the FDA. We are encouraged to learn that the company has received positive feedback on the planned clinical development program for vaccine candidate ALZ-101.
